Literature DB >> 22454073

Overview of alternative oligonucleotide chemistries for exon skipping.

Amer F Saleh1, Andrey A Arzumanov, Michael J Gait.   

Abstract

The chemistry of the oligonucleotide backbone is crucial to obtaining high activity in vivo in exon skipping applications. Apart from the ability to bind strongly and sequence-specifically to pre-mRNA targets, the type of backbone also influences cell delivery, in vivo pharmacology, bio-distribution, toxicology, and ultimately the therapeutic use in humans. Reviewed here are classes of oligonucleotide commonly used for exon skipping applications, namely negatively charged backbones typified by RNA analogues having 2'-O-substitution and a phosphorothioate linkage and charge-neutral backbones such as PNA and PMO. Also discussed are peptide conjugates of PNA and PMO that enhance cellular and in vivo delivery and their potential for drug development. Finally, the prospects for development of other analogue types in exon skipping applications are outlined.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22454073     DOI: 10.1007/978-1-61779-767-5_23

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  20 in total

Review 1.  Antisense mediated splicing modulation for inherited metabolic diseases: challenges for delivery.

Authors:  Belen Pérez; Lluisa Vilageliu; Daniel Grinberg; Lourdes R Desviat
Journal:  Nucleic Acid Ther       Date:  2014-02       Impact factor: 5.486

Review 2.  Genetic diagnosis as a tool for personalized treatment of Duchenne muscular dystrophy.

Authors:  Luca Bello; Elena Pegoraro
Journal:  Acta Myol       Date:  2016-12

3.  Preclinical Safety Assessment of Therapeutic Oligonucleotides.

Authors:  Patrik Andersson
Journal:  Methods Mol Biol       Date:  2022

4.  Covalent conjugation of oligonucleotides with cell-targeting ligands.

Authors:  Md Rowshon Alam; Xin Ming; Osamu Nakagawa; Jian Jin; R L Juliano
Journal:  Bioorg Med Chem       Date:  2013-06-01       Impact factor: 3.641

5.  Development and Application of an Ultrasensitive Hybridization-Based ELISA Method for the Determination of Peptide-Conjugated Phosphorodiamidate Morpholino Oligonucleotides.

Authors:  Umar Burki; Jonathan Keane; Alison Blain; Liz O'Donovan; Michael John Gait; Steven H Laval; Volker Straub
Journal:  Nucleic Acid Ther       Date:  2015-07-15       Impact factor: 5.486

Review 6.  Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases.

Authors:  Kavitha Siva; Giuseppina Covello; Michela A Denti
Journal:  Nucleic Acid Ther       Date:  2014-02       Impact factor: 5.486

7.  Novel Ex Vivo Culture Method for the Study of Dupuytren's Disease: Effects of TGFβ Type 1 Receptor Modulation by Antisense Oligonucleotides.

Authors:  Sofia Karkampouna; Boudewijn Pt Kruithof; Peter Kloen; Miryam C Obdeijn; Annelies Ma van der Laan; Hans J Tanke; Dwi U Kemaladewi; Willem Mh Hoogaars; Peter Ac 't Hoen; Annemieke Aartsma-Rus; Ian M Clark; Peter Ten Dijke; Marie-José Goumans; Marianna Kruithof-de Julio
Journal:  Mol Ther Nucleic Acids       Date:  2014-01-21       Impact factor: 10.183

Review 8.  Bioconjugates for targeted delivery of therapeutic oligonucleotides.

Authors:  Xin Ming; Brian Laing
Journal:  Adv Drug Deliv Rev       Date:  2015-02-15       Impact factor: 15.470

Review 9.  Development of therapeutic splice-switching oligonucleotides.

Authors:  Petra Disterer; Adrianna Kryczka; Yuqi Liu; Yusef E Badi; Jessie J Wong; James S Owen; Bernard Khoo
Journal:  Hum Gene Ther       Date:  2014-06-19       Impact factor: 5.695

Review 10.  Splicing therapy for neuromuscular disease.

Authors:  Andrew G L Douglas; Matthew J A Wood
Journal:  Mol Cell Neurosci       Date:  2013-04-28       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.